-
Maximized Efficiency
ALiCE® is extremely efficient, even for complex multimers or membrane proteins - a wide variety of previously impossible targets are in reach within only 1-2 days
-
Fully Scalable
ALiCE® is the only eukaryotic cell-free system that scales reliably and seamlessly from early research to large-scale production - designed for the full drug development process
-
Simple yet Flexible
ALiCE® is user-friendly and an open-system from start to finish, with no need for lengthy optimization – removing protein expression as your bottleneck
ALiCE® for Research
Looking to do small-scale protein expression? Have a look at ALiCE® for Research.
ALiCE® for Scale-Up
Interested in producing your protein of interest in large amounts? Read more about ALiCE® for Scale-Up
ALiCE® as a Service
Let our team unlock even the most challenging protein targets and reference proteins that traditional systems simply can’t access.
LenioBio Earns Prestigious EU STEP Seal
LenioBio is proud to announce that it has been awarded the prestigious STEP Seal by the European Commission as part of its submission to the EU4Health funding call.
Coming Soon: ALiCE® for HTP
Discover our all-in-one high-throughput protein expression solution—seamlessly integrate DNA and expression for rapid, efficient protein production with minimal preparation time.
Meet ALiCE® – Radical Simple Protein Expression
Experience fast, versatile, and scalable protein production with ALiCE®! Produce proteins in 48 hours with our easy, plug-and-play platform. No protein is too difficult, and you can scale effortlessly to meet your needs.
Our Purpose: To Make Life-Saving Medicines Accessible to All
We believe that everyone deserves an equal chance to lead a healthy life.
That’s why we created ALiCE®, a disruptive cell-free protein technology that will change the way proteins are produced. Our goal? To simplify biomanufacturing and speed up the delivery of drugs to the patient.
A Therapeutic Target Like No Other
With unmatched therapeutic potential, GPCRs account for ~35% of FDA-approved drugs, achieving the status of the most common class of therapeutic target. They also happen to be one of the most challenging classes of protein to express. In this case study, we explore the rapid expression and in-lysate functional analysis of the CB2 GPCR using the ALiCE® expression system.
Plant-Based ALiCE® Technology Could Shave Weeks Off Vaccine Production
LenioBio has received CEPI (Coalition for Epidemic Preparedness Innovations) funding of up to US $2 million to provide preclinical proof-of-concept that their commercially available, plant-based, and cell-free technology can produce proteins for use in clinical trials testing vaccines against epidemic and pandemic threats in 20-40 days.
ALiCE® Unlocks Access To Novel Cancer Target
Receptor tyrosine kinases (RTKs) are promising cancer targets but are notoriously difficult to express. In a recent Nature Scientific Reports article, researchers at Leeds University combined the ALiCE® cell-free protein expression system with copolymer encapsulation to achieve high-yield production of a key oncogenic RTK membrane target.
